State Street Corp Alnylam Pharmaceuticals, Inc. Transaction History

State Street Corp

$2.41 Trillion
Q3 2024

A detailed history of State Street Corp transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, State Street Corp holds 3,468,315 shares of ALNY stock, worth $849 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

3,468,315

Previous 3,534,836 1.88%

Holding current value

$849 Million

Previous $859 Million 11.07%

% of portfolio

0.04%

Previous 0.04%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$233.81 - $287.01 $15.6 Million - $19.1 Million	-66,521 Reduced 1.88%	3,468,315 $954 Million
Q2 2024 Aug 14, 2024	BUY	$143.31 - $247.0 $49.2 Million - $84.8 Million	343,463 Added 10.76%	3,534,836 $859 Million
Q1 2024 May 15, 2024	BUY	$146.51 - $198.2 $10.7 Million - $14.4 Million	72,821 Added 2.34%	3,191,373 $477 Million
Q4 2023 Feb 14, 2024	BUY	$151.41 - $196.57 $33.2 Million - $43.1 Million	219,039 Added 7.55%	3,118,552 $597 Million
Q3 2023 Nov 14, 2023	BUY	$170.77 - $211.65 $1.24 Million - $1.54 Million	7,266 Added 0.25%	2,899,513 $514 Million
Q2 2023 Aug 14, 2023	BUY	$185.01 - $212.05 $6.91 Million - $7.92 Million	37,366 Added 1.31%	2,892,247 $549 Million
Q1 2023 May 15, 2023	BUY	$182.66 - $235.53 $12.5 Million - $16.1 Million	68,339 Added 2.45%	2,854,881 $572 Million
Q4 2022 Feb 14, 2023	SELL	$185.53 - $241.31 $1.66 Million - $2.16 Million	-8,943 Reduced 0.32%	2,786,542 $662 Million
Q3 2022 Nov 15, 2022	SELL	$138.54 - $232.0 $26.8 Million - $44.9 Million	-193,374 Reduced 6.47%	2,795,485 $560 Million
Q2 2022 Aug 15, 2022	BUY	$120.42 - $169.29 $9.56 Million - $13.4 Million	79,369 Added 2.73%	2,988,859 $436 Million
Q1 2022 May 16, 2022	BUY	$127.18 - $173.91 $7.52 Million - $10.3 Million	59,101 Added 2.07%	2,909,490 $475 Million
Q4 2021 Feb 14, 2022	BUY	$159.56 - $209.29 $7.91 Million - $10.4 Million	49,564 Added 1.77%	2,850,389 $483 Million
Q3 2021 Nov 15, 2021	BUY	$169.75 - $207.73 $2.7 Million - $3.3 Million	15,887 Added 0.57%	2,800,825 $529 Million
Q2 2021 Aug 16, 2021	BUY	$128.63 - $176.89 $19.8 Million - $27.3 Million	154,082 Added 5.86%	2,784,938 $472 Million
Q1 2021 May 17, 2021	SELL	$126.83 - $175.69 $22 Million - $30.5 Million	-173,848 Reduced 6.2%	2,630,856 $371 Million
Q4 2020 Feb 16, 2021	BUY	$122.97 - $147.0 $1.54 Million - $1.85 Million	12,552 Added 0.45%	2,804,704 $365 Million
Q3 2020 Nov 10, 2020	BUY	$121.19 - $165.49 $546,082 - $745,697	4,506 Added 0.16%	2,792,152 $407 Million
Q2 2020 Aug 14, 2020	SELL	$104.21 - $156.44 $20.5 Million - $30.7 Million	-196,495 Reduced 6.58%	2,787,646 $413 Million
Q1 2020 May 11, 2020	BUY	$93.12 - $133.99 $278 Million - $400 Million	2,984,141 New	2,984,141 $325 Million

Others Institutions Holding ALNY

# of Institutions

642

Shares Held

109M

Call Options Held

1.28M

Put Options Held

1.21M

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $30.1B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.

Account

State Street Corp Alnylam Pharmaceuticals, Inc. Transaction History